Table 2 Multivariable regression models for objective assessment and TDM performance in the 12 weeks prior to therapy change (either dose change or discontinuation)

Sex (female vs. male)

0.849

0.565–1.274

0.4283

1.480

0.929–2.361

0.0993

Race (white vs. nonwhite)

0.657

0.330–1.306

0.2305

1.152

0.540–2.456

0.7147

Age at therapy change (years)

1.004

0.989–1.019

0.6215

0.996

0.979–1.013

0.6164

Previous biologic use (yes vs. no)

1.027

0.639–1.652

0.9120

0.980

0.5840–1.642

0.9378

Disease duration at therapy change (years)

0.987

0.964–1.011

0.2896

0.997

0.969–1.025

0.8133

Site type (academic vs. community)

1.588

1.010–2.495

0.0452

1.114

0.662–1.875

0.6845

Private insurance at enrollment (yes vs. no)

1.044

0.602–1.811

0.8781

1.188

0.626–2.253

0.5979

Drug class^b

0.0083

 Adalimumab

Ref

Ref

–

Ref

Ref

Ref

 Infliximab

0.569

0.360–0.900

0.0159

0.844

0.529–1.348

0.4779

 Other anti-TNF

1.460

0.576–3.705

0.4252

 Ustekinumab

0.353

0.137–0.914

0.0320

 Vedolizumab

1.359

0.683–2.702

0.3819

Disease type (CD vs. UC)

1.181

0.734–1.901

0.4923

0.953

0.567–1.602

0.8566

Therapy change (discontinuation vs. dose change)

1.178

0.776–1.788

0.4417

1.011

0.634–1.613

0.9632